Not provided
Not provided
Not provided
Not provided
Not provided
The study was terminated after UTSW was informed by Novartis that further support for the study would not be provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Novartis Pharmaceuticals | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to see if Ceritinib can target ALK in non-small cell lung cancer and slow down cancer growth and prevent it from spreading.
This is an, open-label, two-cohort protocol designed to evaluate the activity of targeted therapy and SABR in ALK positive lung adenocarcinoma.
Cohort A will evaluate the combination in ALK-inhibitor naïve patients. Cohort B will evaluate the combination in patients who have received treatment with one prior ALK inhibitor.
Ceritinib will be administered to the patient until disease progression by RECIST 1.1, unacceptable toxicity, withdrawal of consent, or discontinuation of the trial for any other reason including death.
The primary focus of this protocol is identifying response in ALK+ lung cancer patients. Patients with Ventana assay and Vysis FISH probe positive tumors will be treated. Evidence of ALK gene rearrangement will also be considered eligible for the trial.
Primary Objective:
Cohort A: Superiority of ceritinib + SABR median PFS compared to historical control of 10 months (expected to be 20 months)
Endpoint:
Cohort A Median PFS defined as time from initiation of ceritinib until disease progression by RECIST 1.1, unacceptable toxicity, withdrawal of consent, or discontinuation of the trial for any other reason including death.
Primary:
Cohort B: Superiority of ceritinib + SABR median PFS compared to historical control of 7 months.
Endpoint:
Cohort B: Median PFS defined as time from initiation of ceritinib until disease progression by RECIST 1.1, unacceptable toxicity, withdrawal of consent, or discontinuation of the trial for any other reason including death.
Secondary:
Safety:
-Demonstrate safety of ceritinib followed by SABR Describe toxicity and adverse events (CTCAE v.4) compared to historical controls.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ALK-inhibitor naive patients | Experimental | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. |
|
| Patients recieved prior ALK inhibitor | Experimental | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ceritinib | Drug | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival | Number of days until disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions | Baseline until date of first observed disease progression or death, assessed up to 31.7 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival | Overall survival is the percentage of participants alive at the given time point. OS is defined as the time to death from the start of drug therapy. | at 12 months |
| Time to 2nd Subsequent Stereotactic Ablative Radiation |
Not provided
Inclusion Criteria:
Histologically or cytologically confirmed diagnosis of lung adenocarcinoma that demonstrates ALK rearrangement as detected by the approved FISH test (Abbott Molecular Inc), using Vysis breakapart probes (defined as 15% or more positive tumor cells); or the Ventana IHC test. Evidence of rearrangement by gene sequencing tests such as FoundationOne or Caris will also be seen as evidence of ALK abnormality and meeting eligibility requirement.
Patients with no prior ALK-inhibitor therapy will be placed in cohort A, those treated with one prior line of ALK-inhibitor (at any time) will enter cohort B.
Patients will not have any other curative therapeutic option, such as radiation or surgery.
WHO performance status 0-2.
Age ≥18 years.
Patients must have recovered from all toxicities related to any prior anticancer therapies to ≤ Grade 2 (CTCAE v 4.03), provided that any concomitant medication is given prior to initiation of treatment with ceritinib. Exception to this criterion: patients with any grade of alopecia are allowed to enter the treatment.
Adequate organ function: the following laboratory criteria have been met:
Patient must have the following laboratory values or have the following laboratory values corrected with supplements to be within normal limits before the first dose of ceritinib:
Written informed consent for the protocol must be obtained prior to any screening procedures.
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures.
Exclusion Criteria:
Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate).
History of carcinomatous meningitis.
Prior therapy with ceritinib.
Presence or history of a malignant disease other than lung adenocarcinoma that has been diagnosed and/or required therapy within the past year and is undergoing active anticancer treatment. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type.
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).
Patient who has received thoracic radiotherapy to lung fields ≤4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy ≤2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤2 weeks prior to starting study treatment is allowed.
Patient has clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months), such as:
Impaired GI function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily. Although, patients unable to swallow capsules will be allowed to participate in this study, by following the specific instructions on making a slurry of the medication.
Patient has impairment of GI function or GI disease that may significantly alter the absorption of ceritinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
Receiving medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with ceritinib and for the duration of participation (see Appendix 1 Tables):
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and agree to continue for 3 months after the last dose of study treatment. Highly effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
Male sterilization (at least 6 months prior to screening) with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate. For female subjects on the study the vasectomized male partner should be the sole partner for that subject.
Combination of any two of the following (a+b or a+c or b+c):
In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to screening. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
Sexually active males unless they agree to use a condom during intercourse while taking drug and agree to continue for 3 months after the last dose of study treatment. Male patients for 3 months should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
Patient has other severe, acute, or chronic medical conditions including uncontrolled diabetes mellitus or psychiatric conditions or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results.
Patient has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure. Video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment ≥1 week after these procedures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Saad Khan, MD | UT Southwetern Medical Center-Oncology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UT Southwestern Medical Center | Dallas | Texas | 75390 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | ALK-inhibitor Naive Patients | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. Ceritinib: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. Stereotactic ablative body radiation: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). |
| FG001 | Patients Recieved Prior ALK Inhibitor | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. Ceritinib: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. Stereotactic ablative body radiation: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
1 patient withdrew consent before thier first scan.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | ALK-inhibitor Naive Patients | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. Ceritinib: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. Stereotactic ablative body radiation: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Progression Free Survival | Number of days until disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions | Posted | Mean | Full Range | days | Baseline until date of first observed disease progression or death, assessed up to 31.7 months. |
|
Baseline until date of first observed disease progression or death, an average of 12 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | ALK-inhibitor Naive Patients | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. Ceritinib: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. Stereotactic ablative body radiation: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| hyperglycemia | Metabolism and nutrition disorders | CTCAE v.4 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | Gastrointestinal disorders | CTCAE v.4 | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Sawsan Rashdan | UT Southwestern Medical Center | 214-648-4180 | Sawsan.Rashdan@UTSouthwestern.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 9, 2020 | Oct 21, 2021 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| C586847 | ceritinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Stereotactic ablative body radiation | Radiation | Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). |
|
After the initial SABR to persisting lesions, if new lesions appear or if existing lesions enlarge but are amenable to SABR, patients will remain on study and listed as not having progressed. Time from start of systemic therapy to first day of second course of SABR
| 18 hours |
| Time to 3rd Subsequent Stereotactic Ablative Radiation (SABR) | Time from start of therapy to first day of third course of SABR was measured. | 3 months |
| Number of Patients With CR/PR/Stable Disease for 6 Months | Number of patients with CR/PR/stable disease for 6 months was measured by evaluating target lesions. Complete Response (CR): Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. | At 6 months |
| Number of Patients With CR/PR/Stable Disease for 12 Months | Number of patients with CR/PR/stable disease for 12 months was measured by evaluating target lesions. Complete Response (CR): Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. | at 12 months |
| Number of Participants With Adverse Events | up to 12 months |
| BG001 | Patients Recieved Prior ALK Inhibitor | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. Ceritinib: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. Stereotactic ablative body radiation: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Patients Recieved Prior ALK Inhibitor | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. Ceritinib: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. Stereotactic ablative body radiation: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). |
|
|
| Secondary | Overall Survival | Overall survival is the percentage of participants alive at the given time point. OS is defined as the time to death from the start of drug therapy. | Posted | Count of Participants | Participants | at 12 months |
|
|
|
| Secondary | Time to 2nd Subsequent Stereotactic Ablative Radiation | After the initial SABR to persisting lesions, if new lesions appear or if existing lesions enlarge but are amenable to SABR, patients will remain on study and listed as not having progressed. Time from start of systemic therapy to first day of second course of SABR | No patients received a second course of SABR | Posted | 18 hours |
|
|
| Secondary | Time to 3rd Subsequent Stereotactic Ablative Radiation (SABR) | Time from start of therapy to first day of third course of SABR was measured. | Data was not collected due to early termination of the study since no participant received 3rd SABR. | Posted | 3 months |
|
|
| Secondary | Number of Patients With CR/PR/Stable Disease for 6 Months | Number of patients with CR/PR/stable disease for 6 months was measured by evaluating target lesions. Complete Response (CR): Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. | Posted | Count of Participants | Participants | At 6 months |
|
|
|
| Secondary | Number of Patients With CR/PR/Stable Disease for 12 Months | Number of patients with CR/PR/stable disease for 12 months was measured by evaluating target lesions. Complete Response (CR): Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. | Posted | Count of Participants | Participants | at 12 months |
|
|
|
| Secondary | Number of Participants With Adverse Events | Posted | Count of Participants | Participants | up to 12 months |
|
|
|
| 0 |
| 8 |
| 1 |
| 8 |
| 8 |
| 8 |
| EG001 | Patients Recieved Prior ALK Inhibitor | Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months. Ceritinib: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. Stereotactic ablative body radiation: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). | 0 | 5 | 2 | 5 | 5 | 5 |
| hyperbilirubinemia | Hepatobiliary disorders | CTCAE v.4 | Systematic Assessment |
|
| Altered Mental Status | Psychiatric disorders | CTCAE v.4 | Systematic Assessment |
|
| influenza | Infections and infestations | CTCAE v.4 | Systematic Assessment |
|
| pleural effusion | Respiratory, thoracic and mediastinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Acid Reflux | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Alkaline phosphatase increased | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Increased ALT | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Anemia | Blood and lymphatic system disorders | CTCAE v.4 | Systematic Assessment |
|
| Appetite Change (dysgeusia, anorexia, decreased appetite) | Metabolism and nutrition disorders | CTCAE v.4 | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | CTCAE v.4 | Systematic Assessment |
|
| Increased AST | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Pain - Back | Injury, poisoning and procedural complications | CTCAE v.4 | Systematic Assessment |
|
| Benign Familial Tremmors | Congenital, familial and genetic disorders | CTCAE v.4 | Systematic Assessment |
|
| Edema | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Blurred Vision | Eye disorders | CTCAE v.4 | Systematic Assessment |
|
| Pain - BL Foot | Injury, poisoning and procedural complications | CTCAE v.4 | Systematic Assessment |
|
| Bradycardia | Cardiac disorders | CTCAE v.4 | Systematic Assessment |
|
| Burning sensation | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Chest Pain | Cardiac disorders | CTCAE v.4 | Systematic Assessment |
|
| Claustrophobia | Psychiatric disorders | CTCAE v.4 | Systematic Assessment |
|
| cold | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Hypertnesion | Hepatobiliary disorders | CTCAE v.4 | Systematic Assessment |
|
| Hypercholesterolemia | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Hyperglycemia | Metabolism and nutrition disorders | CTCAE v.4 | Systematic Assessment |
|
| Hypophosphatemia | Metabolism and nutrition disorders | CTCAE v.4 | Systematic Assessment |
|
| Increased Creatinine | Renal and urinary disorders | CTCAE v.4 | Systematic Assessment |
|
| cough | General disorders | CTCAE v.4 | Systematic Assessment |
|
| intraoperative ear injury | Injury, poisoning and procedural complications | CTCAE v.4 | Systematic Assessment |
|
| Decreased ANC | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Decreased calcium | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Depression | Psychiatric disorders | CTCAE v.4 | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Impaired Balance | Injury, poisoning and procedural complications | CTCAE v.4 | Systematic Assessment |
|
| Dizziness | Nervous system disorders | CTCAE v.4 | Systematic Assessment |
|
| Disequilibrium | Nervous system disorders | CTCAE v.4 | Systematic Assessment |
|
| Discomfort in the sciatic nerve right leg | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Discomfort left side of rib cage | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Increased GGT | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Increased Lipase | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Erectile dysfunction | Reproductive system and breast disorders | CTCAE v.4 | Systematic Assessment |
|
| Fatigue | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Fever | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Flu like symptoms (achy,warm) | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Headache | Nervous system disorders | CTCAE v.4 | Systematic Assessment |
|
| Heartburn | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Herpes Simplex | Immune system disorders | CTCAE v.4 | Systematic Assessment |
|
| Increased amylase | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Increased blood bilirubin | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | CTCAE v.4 | Systematic Assessment |
|
| Increased lymphocyte | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | CTCAE v.4 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Vomitting | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Intermittent bloating | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Influenza | Infections and infestations | CTCAE v.4 | Systematic Assessment |
|
| Pain- Knee | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Intermittent hand and finger spasms | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Rash | Immune system disorders | CTCAE v.4 | Systematic Assessment |
|
| stomach cramps | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Itching | Skin and subcutaneous tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Latent tuberculosis | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Tooth Infection | Gastrointestinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Low albumin | Metabolism and nutrition disorders | CTCAE v.4 | Systematic Assessment |
|
| Malignant pericardial effusion | Cardiac disorders | CTCAE v.4 | Systematic Assessment |
|
| Neck Pain | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Orthostatic hypotension | Vascular disorders | CTCAE v.4 | Systematic Assessment |
|
| Osteoarthritis | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Pain - right lung, shoulder | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Right Leg/Hip Pain | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Right shoulder pain | Musculoskeletal and connective tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Pain - General | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Palpitations | Cardiac disorders | CTCAE v.4 | Systematic Assessment |
|
| Pleural Effusion | Respiratory, thoracic and mediastinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Pneumonia | Infections and infestations | CTCAE v.4 | Systematic Assessment |
|
| Prolonged QT | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Prostatitis | Reproductive system and breast disorders | CTCAE v.4 | Systematic Assessment |
|
| Pruritus (hands) | Skin and subcutaneous tissue disorders | CTCAE v.4 | Systematic Assessment |
|
| Seasonal allergies | Immune system disorders | CTCAE v.4 | Systematic Assessment |
|
| Sinus Infection | Infections and infestations | CTCAE v.4 | Systematic Assessment |
|
| Skin infections: shingles | Infections and infestations | CTCAE v.4 | Systematic Assessment |
|
| Snoring | Respiratory, thoracic and mediastinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Sore throat | Respiratory, thoracic and mediastinal disorders | CTCAE v.4 | Systematic Assessment |
|
| T wave abnormality | Cardiac disorders | CTCAE v.4 | Systematic Assessment |
|
| Tachycardia | Vascular disorders | CTCAE v.4 | Systematic Assessment |
|
| Tranaminatis | General disorders | CTCAE v.4 | Systematic Assessment |
|
| Trapped Lung | Respiratory, thoracic and mediastinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Upper respiratory infection | Infections and infestations | CTCAE v.4 | Systematic Assessment |
|
| Urinary Tract Infection | Infections and infestations | CTCAE v.4 | Systematic Assessment |
|
| Vertigo | Ear and labyrinth disorders | CTCAE v.4 | Systematic Assessment |
|
| Weight loss | Investigations | CTCAE v.4 | Systematic Assessment |
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | CTCAE v.4 | Systematic Assessment |
|
| Worsening Allergies | Investigations | CTCAE v.4 | Systematic Assessment |
|
Not provided
Not provided
Not provided